| MYELODYSPLASTIC SYNDROME
Tibsovo vs Inqovi
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Tibsovo vs Inqovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInqovi has a higher rate of injection site reactions vs Tibsovo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Inqovi but not Tibsovo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tibsovo
Inqovi
At A Glance
Oral
Daily
IDH1 inhibitor
Oral
Once daily, Days 1-5 of each 28-day cycle
Nucleoside metabolic inhibitor
Indications
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
- MYELODYSPLASTIC SYNDROME
- Refractory anemias
- Refractory anemia with ringed sideroblasts
- Refractory anaemia with excess blasts
- Leukemia, Myelomonocytic, Chronic
Dosing
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME, Refractory anemias, Refractory anemia with ringed sideroblasts, Refractory anaemia with excess blasts, Leukemia, Myelomonocytic, Chronic 1 tablet (35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle, taken on an empty stomach; minimum of 4 cycles until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Most common (>=20%) fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, transaminase increased
Serious febrile neutropenia, pneumonia, sepsis
Postmarketing differentiation syndrome, interstitial lung disease, cardiomyopathy
Pharmacology
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis; cedazuridine inhibits cytidine deaminase in the gastrointestinal tract and liver to increase systemic exposure of orally administered decitabine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
Inqovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Inqovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Inqovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tibsovo.
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TibsovoView full Tibsovo profile
InqoviView full Inqovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.